Hassane NJIMI

Mr. Hassane NJIMI

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
TTThomas Luz Teixeira
Thomas Luz Teixeira
Lorenzo PelusoLorenzo Peluso
Lorenzo Peluso
PBPierluigi Banco
Pierluigi Banco
HNHassane NJIMI
Hassane NJIMI
LALayal Abi-Khalil
Layal Abi-Khalil
Fabio Silvio TacconeFabio Silvio Taccone
Fabio Silvio Taccone
Background: The aim of this study was to evaluate whether the early assessment of neurological pupil index (NPi) values derived from automated pupillometry could predict neurological outcome after traumatic brain injury (TBI). Methods: Retrospective observational study including adult (>18 years) TBI patients admitted from January 2018 to December 2020, with available NPi on admission. Abnormal NPi was considered if <3. Unfavorable neurological outcome (UO) at hospital discharge was considered for a Glasgow Outcome Scale of 1–3. Results: 100 patients were included over the study period (median age 48 (34–69) years and median GCS on admission 11 (6–15)); 49 (49%) patients had UO. On admission, 20 (20%) patients had an abnormal NPi (NPi < 3); median worst (i.e., from both eyes) NPi was 4.2 (3.2–4.5). Median worst and mean NPi on admission were significantly lower in the UO group than others (3.9 (1.7–4.4) vs. 4.4 (3.7–4.6); p = 0.005–4.0 (2.6–4.5) vs. 4.5 (3.9–4.7); p = 0.002, respectively). The ROC curve for the worst and mean NPi showed a moderate accuracy to predict UO (AUC 0.66 (0.56–0.77); p = 0.005 and 0.68 (0.57–0.78); p = 0.002). However, in a generalized linear model, the prognostic role of NPi on admission was limited. Conclusions: Low NPi on admission has limited prognostic value in TBI.

25 October 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
APAmandine Polain
Amandine Polain
JGJulie Gorham
Julie Gorham
IRImmacolata Romeo
Immacolata Romeo
MBMirko Belliato
Mirko Belliato
Lorenzo PelusoLorenzo Peluso
Lorenzo Peluso
Fabio Silvio TacconeFabio Silvio Taccone
Fabio Silvio Taccone
Background: The aim of this study was to identify predictors of insufficient beta-lactam concentrations in patients undergoing extracorporeal membrane oxygenation (ECMO). Methods: Retrospective analysis of all patients receiving ECMO support and treated with ceftazidime or cefepime (CEF), piperacillin/tazobactam (TZP), or meropenem (MEM). Trough drug concentrations (Cmin) were measured before the subsequent dose, according to the decision of the attending physician. Insufficient drug concentrations were identified if Cmin was below the clinical breakpoint of Pseudomonas aeruginosa. Results: A total of 222 Cmin (CEF, n = 41; TZP, n = 85; MEM, n = 96) from 110 patients were included; insufficient concentrations were observed in 26 (12%) antibiotic assessments; 21 (81%) of those occurred during MEM therapy. Insufficient Cmin were associated with a shorter time from initiation of antibiotics to measurement, a lower single dose of antibiotic, a higher creatinine clearance (CrCL), lower sequential organ failure assessment (SOFA) scores, and less use of continuous renal replacement therapy (CRRT) when compared to others. Conclusions: Insufficient broad-spectrum beta-lactam concentrations were observed in 12% of drug measurement during ECMO therapy. Higher than recommended drug regimens could be considered in the very early phase of therapy and in those patients with augmented renal clearance and with less severe organ dysfunction.

Verified
Journal Article
Open access
PDF file
KWKatharina Charlotte Wunderlich
Katharina Charlotte Wunderlich
CCCarmen Orte Cano
Carmen Orte Cano
MSMariano Suppa
Mariano Suppa
OGOlivier Gaide
Olivier Gaide
JWJ. M. White
J. M. White
VMVéronique DEL MARMOL
Véronique DEL MARMOL
Background: Basal cell carcinoma (BCC) is the most common skin cancer worldwide, with a multifactorial aetiology involving environmental and intrinsic factors. A small subset of patients develops high-frequency BCC (HF-BCC), defined as ≥9 BCCs within 3 years. Objective: To analyse demographic, clinical, and histopathological features of non-syndromic HF-BCC in a Belgian cohort, compared with low-burden BCC patients and healthy controls. Methods: A retrospective cohort study was conducted at Erasme Hospital (Brussels) using data from the EUSCAP platform. Clinical, behavioural, and histopathological data were collected and statistically analysed. Results: Of 783 patients, 16 with HF-BCC were identified. For comparison, 32 patients with 1–2 BCCs and 117 patients without BCC were selected. HF-BCC patients showed distinct characteristics, including a higher proportion of superficial BCCs (68.3% vs. 50%, p = 0.01) and fewer nodular subtypes (43.2% vs. 63.5%, p = 0.01). Their tumours were less frequently located on the nose and ears compared with patients having 1–2 BCCs. HF-BCC was associated with a personal history of squamous cell carcinoma (SCC) and actinic keratosis (AK). Conclusions: HF-BCC patients display distinct anatomical, histopathological and clinical characteristics, with a predominance of superficial BCC and an association with a personal history of SCC and AK. They show a lower frequency of tumours on the nose and ears, with a stronger tendency for localisation on the trunk and extremities. Identifying risk factors and genetic markers may contribute to improved early detection strategies, preventive measures, and the development of targeted therapies.

1 August 2025 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
KHKatarina Winant Halenarova
Katarina Winant Halenarova
DBDaniel De Backer
Daniel De Backer
HNHassane NJIMI
Hassane NJIMI
FTFabio Silvio Taccone
Fabio Silvio Taccone
LOluc Van Obbergh
luc Van Obbergh

16 July 2026 in JHEP Reports
Verified
Journal Article
Open access
CMChristophe Moreno
Christophe Moreno
PDPierre Deltenre
Pierre Deltenre
AMAstrid Marot
Astrid Marot
HNHassane NJIMI
Hassane NJIMI
LLLuc Lasser
Luc Lasser
SDSergio Negrin Dastis
Sergio Negrin Dastis
Severe alcohol-related hepatitis (AH) has high short-term mortality, and corticosteroid therapy is recommended in the absence of contraindications. However, its benefit in patients with early spontaneous bilirubin improvement remains unknown. We determined whether corticosteroid therapy improves survival compared with placebo in this specific population. In this multicenter, randomized, placebo-controlled trial conducted in 10 Belgian hospitals (February 2018-May 2024), patients aged ≥18 years with biopsy-proven severe AH and spontaneous bilirubin decline >10% between admission and day 5-10 were randomized 1:1 to methylprednisolone 32 mg daily or placebo for 28 days. The primary outcome was 90-day survival; other outcomes included 30-day survival and cumulative incidence of infection at 90 days. Sixty-nine of the 140 planned patients were analyzed (38 corticosteroid, 31 placebo), representing 49% of the planned sample size. Baseline characteristics were well balanced. At 90 days, survival was 79% (95% CI, 67%-93%) versus 83% (95% CI, 70%-98%) (hazard ratio, 1.19; 95% CI, 0.39-3.63; P=0.76). Eight deaths occurred in the corticosteroid arm versus 5 in the placebo arm. At 30 days, survival was 95% versus 94% (P=0.83). Cumulative incidence of infection at 90 days was 47% versus 34% (subdistribution hazard ratio, 1.55; 95% CI, 0.72-3.34; P=0.26). Lille score was an independent predictor of 90-day mortality. In patients with severe AH and early spontaneous bilirubin improvement, corticosteroid therapy was not associated with improved survival, but the underpowered trial cannot exclude a benefit. A short observation period after admission may help identify patients who can be managed without corticosteroids. Corticosteroid therapy is recommended for patients with severe alcohol-related hepatitis (AH), but whether this benefit extends to the subgroup who show early spontaneous improvement in bilirubin after admission was previously unknown. In this multicenter, randomized, placebo-controlled trial, corticosteroid therapy was not associated with improved 90-day or 30-day survival in patients with severe, biopsy-proven AH and a spontaneous bilirubin decline greater than 10% within 5 to 10 days of admission, and was associated with a numerically higher, though not statistically significant, risk of infection. These findings are most relevant to hepatologists and other clinicians managing patients with severe AH, and to researchers designing future AH trials, as they identify a subgroup in whom the benefit of corticosteroids is uncertain. They support a risk-stratified approach in which a brief observation period after admission-incorporating bilirubin trend, infection screening, and liver biopsy-may help identify patients with a relatively favorable prognosis who can be spared corticosteroid therapy and its associated risks. However, because the trial was stopped early after enrolling only 69 of the 140 planned patients, it was underpowered, and a modest survival benefit of corticosteroids cannot be excluded. These results should therefore not be interpreted as definitive evidence against corticosteroid use in this population and require confirmation in larger, adequately powered studies before informing clinical guidelines or being generalized beyond this specific patient subgroup. ClinicalTrials.gov (NCT03160651), EudraCT number: 2016-005136-16.

4 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AGAurora Gaeta
Aurora Gaeta
MSMariano Suppa
Mariano Suppa
HNHassane NJIMI
Hassane NJIMI
NPNikolay Nikolaevich Potekaev
Nikolay Nikolaevich Potekaev
ASAlexandros Stratigos
Alexandros Stratigos
VMVéronique DEL MARMOL
Véronique DEL MARMOL
Background: In 2009, the International Agency for Research on Cancer (IARC) classified UV-emitting tanning devices as carcinogenic to humans (Group 1). This study aimed to describe ten-year trends in sunbed use prevalence across Europe and examine differences by country and sociodemographic and phenotypic characteristics. Methods: Euromelanoma survey data collected between 2009 and 2018 from 33 countries were analysed among individuals voluntarily attending free skin examinations. Annual sunbed use prevalence and 95% confidence intervals were estimated by country, with stratified analyses by gender, age, education level, and skin phototype. Associations with sunbed use were investigated using mixed-effects logistic regression models. Results: A total of 343,675 participants were included. Among Euromelanoma campaign participants, current sunbed use declined over the study period, declining from approximately 12.8% in 2009 to below 6% by 2018, despite year-to-year fluctuations. Women, adults aged 20–35 years and individuals with skin phototypes III–IV exhibited the highest odds of sunbed use (OR Female vs. Male = 3.01, 95%CI [2.91–3.12], OR 20–35 vs. >35 = 2.54, 95%CI [2.47–2.61], and OR Type III–IV vs. Type I–II = 1.52, 95%CI [1.47–1.56], respectively). Marked heterogeneity was observed across countries. Mixed-effects analyses showed a strong temporal decline that was significantly steeper among younger participants, particularly those aged 20–35 years, than among individuals older than 35 years. Conclusions: Indoor tanning prevalence declined across Europe between 2009 and 2018, during a period of evolving post-IARC regulatory and preventive measures. Persistent sociodemographic disparities and substantial between-country heterogeneity highlight the need for targeted, country-specific prevention strategies and continued monitoring of indoor tanning behaviors.